PPIDT00375
Drug Information
| Name | Albutrepenonacog alfa |
|---|---|
| Sequence | YNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAETVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGRSALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLTPVSQTSKLTRAETVFPDVDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL |
| DrugBank_ID | DB13884 |
| Type | biotech |
| Indication | Under the EMA and FDA, rIX-RFP is indicated in the treatment of hemophilia B.[L2306] For Health Canada, rIX-FRP is also indicated to prevent or reduce bleeding episodes.[L2305] Hemophilia B is the second most common type of hemophilia. It is a rare inherited bleeding disorder caused by reduced or absent levels of factor IX (FIX). The FIX is a vitamin K-dependent plasma protease that when activated is involved in the blood coagulation cascade.[A32551] The hemophilia B is caused by mutations in the _FIX_ gene which can cause different phenotypes. The severe form is characterized by the presence of spontaneous and recurring bleeds into the joints and muscles and excessive bleeding after trauma or surgery.[A32552] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Solution | Intravenous |
250 UI
|
| Injection, powder, for solution | Intravenous |
3500 IU
|
| Injection, powder, for solution | Parenteral |
1000 IU
|
| Injection, powder, for solution | Parenteral |
2000 IU
|
| Injection, powder, for solution | Parenteral |
250 IU
|
| Injection, powder, for solution | Parenteral |
500 IU
|
| Injection, powder, lyophilized, for solution; kit | Intravenous |
1000 [iU]/2.5mL
|
| Injection, powder, lyophilized, for solution; kit | Intravenous |
2000 [iU]/5mL
|
| Injection, powder, lyophilized, for solution; kit | Intravenous |
250 [iU]/2.5mL
|
| Injection, powder, lyophilized, for solution; kit | Intravenous |
3500 [iU]/5mL
|
| Injection, powder, lyophilized, for solution; kit | Intravenous |
500 [iU]/2.5mL
|
| Kit; powder, for solution | Intravenous |
250 unit / vial
|
| Kit; powder, for solution | Intravenous |
3500 unit / vial
|
| Injection, powder, for solution | Intravenous |
1000 IU
|
| Injection, powder, for solution | Intravenous |
2000 IU
|
| Injection, powder, for solution | Intravenous |
250 IU
|
| Injection, powder, for solution | Intravenous |
500 IU
|
| Injection, powder, lyophilized, for solution | Intravenous |
1000 IU/Vial
|
| Injection, powder, lyophilized, for solution | Intravenous |
2000 IU
|
| Injection, powder, lyophilized, for solution | Intravenous |
250 IU
|
| Injection, powder, lyophilized, for solution | Intravenous |
500 IU
|
| Injection, powder, for solution | — |
1000 IU/1vial
|
| Injection, powder, for solution | — |
250 IU/1vial
|
| Injection, powder, for solution | — |
500 IU/1vial
|